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identify those HD patients who might have a benefit of carni-Anemia and carnitine supplementation in hemodialyzed pa-
tine supplementation, as well as studies concerning the optimaltients. Carnitine supplementation in hemodialyzed patients was
dosage, duration, and way of administration of carnitine sup-studied in a double-blinded, randomized, controlled trial in
plementation and its mechanism of action, are required.order to elucidate the effect of intravenous carnitine on renal
anemia in patients treated with recombinant human erythro-
poietin (rHuEPO).
Twenty stable hemodialysis (HD) patients received intrave-
Anemia is a common finding in patients with end-nous L-carnitine after each dialysis session in a dosage of 5
(N 5 15) and 25 (N 5 5) mg/kg, respectively, together with stage renal failure and is present in a vast majority of
intravenous iron saccharate (20 mg/HD session) for four patients requiring maintenance hemodialysis (HD) or
months and without iron for a further four months. Twenty peritoneal dialysis therapy. The most important reasonpatients received placebo instead of carnitine with an identical
for anemia is inadequate erythropoiesis caused by de-iron regimen. After a run-in phase of six months with a stable
creased erythropoietin production of the diseased kid-rHuEPO requirement, the rHuEPO dose was adjusted monthly
when necessary to maintain target hemoglobin levels. At study neys. The efficacy of recombinant human erythropoietin
entry (T0), plasma and red blood cell carnitine levels did not (rHuEPO) in the treatment of renal anemia could be
correlate significantly with the rHuEPO requirement. How-
confirmed in numerous studies [1].ever, plasma free and total carnitine levels showed a significant
However, as renal anemia is of multifactorial origin,negative correlation with erythrocyte survival time at T0. After
four months of coadministration of intravenous iron and a considerable proportion of patients shows rHuEPO
L-carnitine (T4), the rHuEPO requirement decreased in 8 of hyporesponsiveness because of the presence of other
19 evaluable HD patients. In these responders, the weekly
etiological factors. The most common is iron deficiency,rHuEPO dose was decreased significantly by 36.9 6 23.3%
and iron supplementation has successfully been used to(183.7 6 131.7 at T0 vs. 126.6 6 127.9 U/kg/week at T4, P ,
0.001). The rHuEPO requirement, however, was unchanged reduce rHuEPO dosage [2]. Other mechanisms of de-
when all carnitine-treated patients were compared between T0 creased erythropoiesis are folate and vitamin B12 defi-
and T4 (T0: 172.0 6 118.0 vs. T4: 152.3 6 118.8 U/kg/week, P 5 ciency [3], secondary hyperparathyroidism [4], aluminum0.07, NS), but the erythropoietin resistance index decreased
toxicity [5], inflammation, malignancy [6], and circulatingsignificantly in this group (T0: 16.0 6 11.0 vs. T4: 13.6 6 10.5
uremic factors, such as spermine [7]. In addition, de-U/kg/week/g of hemoglobin, P , 0.02).
The erythrocyte survival time was measured in five HD pa- creased red blood cell (RBC) survival by hemolysis or
tients treated with iron and carnitine at T0 and T4. Two out hypersplenism and chronic intestinal blood loss as well
of these patients were carnitine responders and showed an
as multiple blood sampling are clinically significant rea-increase of erythrocyte survival time of 15 and 20%, respec-
sons for rHuEPO hyporesponsiveness [8, 9].tively.
After the withdrawal of iron supplementation, the rHuEPO Furthermore, disturbances in carnitine metabolism
requirement increased comparably in both L-carnitine- and contribute to the development of renal anemia in HD
placebo-treated patients during four more months.
patients, and a beneficial effect of carnitine supplementa-According to our data, L-carnitine, in addition to iron supple-
tion on renal anemia has been reported in studies beforementation, may have an effect on erythropoietin resistance and
erythrocyte survival time in HD patients. More than half of [10–13] and after [14–17] the introduction of rHuEPO.
our patients, however, showed no benefit. Further studies to This article reviews the literature on carnitine metabo-
lism in HD patients, especially with respect to possible
mechanisms affecting anemia, and reports our own resultsKey words: erythropoietin, dialysis, vitamin supplements, end-stage
renal disease, renal anemia. concerning the effect of carnitine supplementation on the
rHuEPO requirement in maintenance dialysis patients. 1999 by the International Society of Nephrology
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CARNITINE METABOLISM AND acyl carnitines across the mitochondrial membrane. In
the mitochondrial matrix, acyl carnitine transferase IIPHYSIOLOGICAL FUNCTIONS
reconverts acyl carnitine esters to acylCoA, and acti-In humans, carnitine [L-(2)-3-hydroxy-4-thrimethyl-
vated fatty acids can undergo b-oxidation [25].aminobutyrate, molecular weight 162 Da] is synthesized
Additionally, carnitine is required for the export ofin liver, kidney, and brain from the essential amino acids
short-chain acyl residues from both the mitochondrialysine and methionine. Cofactors for L-carnitine synthe-
and peroxisomes. The export of acetyl carnitine out ofsis are vitamin C, niacin, pyridoxal phosphate, 2-oxoglu-
mitochondria predominantly occurs when acetylCoAtarate, NAD1 , and iron. Only liver and kidney release
formation exceeds its utilization in the Krebs cycle andnewly synthesized carnitine into systemic circulation [18].
is dependent on the intramitochondrial availability ofL-carnitine is also obtained from diet almost exclusively
free carnitine. Accumulation of acetylCoA inhibits pyru-from foods of animal origin and is 54 to 87% bioavailable
vate dehydrogenase activity, and the enzyme activity wasfrom normal Western diets, with an absorption rate de-
shown to be stimulated by L-carnitine supplementationpending on the amount ingested. In part, dietary carni-
[26]. Furthermore, carnitine modulates the intramitochon-tine is metabolized by gastrointestinal microorganisms,
drial ratio of acylCoA to free CoA by the formation anddepending on the level of carnitine intake [19].
export of acyl carnitine, thus increasing free CoA, which,Ninety-eight percent of total body carnitine is located
in turn, modulates key mitochondrial processes [27].in cardiac and skeletal muscles, 1.5% in liver and kidney,
The export of branched chain acyl groups out of mito-and 0.5% in extracellular fluid [20]. In blood, carnitine
chondria is critical in the catabolism of branched chainis present in plasma and cells, predominately RBCs [21].
amino acids. Additionally, carnitine is involved in trap-Plasma and RBCs are considered to be metabolically
ping and elimination of unphysiological acyl groups asdistinct compartments. In both compartments, free carni-
valproic acid [26]. In organic acid metabolism disorders,tine, short-chain acyl carnitine (predominantly acetyl),
carnitine is required for the excretion of accumulatedand long-chain acyl carnitine are present [22].
acylCoA compounds. Chalmers et al proposed a relative
Glomerulary filtered carnitine is highly conserved by
lack of free carnitine compared with the metabolic needs
the kidney at normal concentrations in plasma, with re- in those pathologic states (“carnitine insufficiency”) and
absorption rates of more than 84%. In rat cortical brush demonstrated increased urinary specific acyl carnitine
border membrane vesicles, sodium gradient-dependent excretion with carnitine supplementation [27].
carrier-mediated carnitine uptake could be demonstrated L-carnitine deficiency therefore leads to the accumula-
[23]. Total urinary excretion varies between 100 and 400 tion of free fatty acids in cell cytoplasm and of acylCoA
mmol/day and is higher in men than in women. The in the mitochondria, producing a toxic effect on the cell
distribution of carnitine fractions in urine is 46% for free through a detergent action. As a consequence, the use
carnitine, 9% for acetyl carnitine, 29% for other short- of fatty acids for energy production is disturbed [18].
chain acyl carnitine, and 16% for long-chain acyl carni- The significance and metabolic function of RBC carni-
tine [24]. Intact kidney function therefore contributes to tine are not now completely understood, as its presence
the normal free to total carnitine ratio by preferential in a purely glycolytic cell lacking mitochondria was un-
reabsorption of free carnitine. clear up to the 1990s. Cooper et al suggested that the
Plasma total carnitine levels in healthy adults are in- presence of carnitine in mature RBCs might be vestigal
fluenced by age and sex: Males were reported to have from the process of hematopoiesis without further func-
significantly higher levels compared with females, and tion [28].
carnitine levels positively correlated to age in females. Ramsay et al, however, demonstrated RBCs to contain
This might be attributable to an estradiol effect, as fe- carnitine palmitoyl transferase (CPT) catalyzing the re-
males below the age of 40 display significantly lower versible transfer of acyl moiety form CoA to L-carnitine
levels compared with women above the age of 40 and [29]. Arduini et al showed L-carnitine to affect RBC
compared with men. Erythrocyte total carnitine levels membrane deformability [30], and Butterfield and Ran-
did not show any age and sex difference [21]. gachari [31] confirmed their suggestion of an specific
The main physiological function of carnitine is the interaction of L-carnitine with cytoskeletal components,
transport of long-chain fatty acids to the sites of b-oxida- strengthening the interaction between spectrin and actin.
tion in the mitochondrial matrix involving several en- Furthermore, CPT affects the realcylation process of
zymes. Briefly, long-chain fatty acids are incorporated membrane phospholipids in RBCs by modulating the
into acyl coenzyme A (acylCoA) in the presence of CoA size of the acylCoA pool [32], which is a major part of
and adenosine triphosphate (ATP). Acyl carnitine trans- the membrane repair process. Activation of cytosolic
ferase I esterifies acylCoA and free carnitine to acyl long-chain fatty acids to their CoA esters by acylCoA
carnitines and carnitine translocase, located in the inner synthetase requires free CoA. The RBC acyl carnitine
pool additionally serves as a reservoir of activated acylmitochondrial membrane, and facilitates transport of
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groups in this process at no cost of ATP [32, 33]. The Data on changes in RBC carnitine levels during HD
sessions are rare: Wanner et al reported unchanged RBCaddition of L-carnitine to RBCs stored at 48C had a
beneficial effect on in vivo viability, increasing signifi- total, free, and acyl carnitine levels in patients treated
with 1 mg/kg intravenous L-carnitine after HD; in pa-cantly the life span of transfused RBCs [34].
tients treated with 5 mg/kg who showed significantly
elevated values of all carnitine fractions compared with
CARNITINE DISTURBANCES IN
untreated patients, HD caused a decrease of RBC short-
HEMODIALYSIS PATIENTS
and long-chain acyl carnitines, whereas free carnitines
In 1974, Bo¨hmer et al were the first to report increased and total carnitines remained unchanged [41].
plasma free carnitine levels in chronic renal failure In maintenance HD patients, predialysis serum free
(CRF) and carnitine deficiency (decreased plasma free carnitine levels were lower compared with healthy con-
carnitine) in patients on maintenance HD. Free carnitine trols in a majority of published data [35–38]. Some au-
decreased to 25% of predialysis values during hemodial- thors, in contrast, found levels comparable [42] or even
ysis sessions [35]. Since that time, carnitine status of higher [43, 44] than in healthy controls [36].
dialysis patients has been studied by numerous investiga- Considering only recently published studies evaluating
tors, and the relief of multiple uremic symptoms by carni- the whole pattern of carnitine, plasma predialysis total
tine supplementation has been reported in conflicting carnitine levels are equal or even higher than in controls,
studies [36]. Up to 1983, mainly free plasma carnitine whereas free carnitine levels are decreased. Throughout
values were reported in the literature, and studies there- the literature, an increase in short-chain acyl carnitine
after revealed a profound difference in uremic patients levels has been reported, thus leading to a significant
between total and free carnitine values. Therefore, care- increase in acyl to free carnitine ratio (decreased free to
ful attention must be paid in comparing different studies. total carnitine ratio) [36].
During HD sessions, a marked decrease in serum car- Erythrocyte carnitine levels behave differently in HD
nitine values compromising all carnitine fractions has patients: Total carnitine is elevated because of a marked
been reported [37], which resulted in a marked increase increase of intracellular free carnitine, whereas short-
in acyl to free carnitine ratio (decreased free to total and long-chain acyl carnitines are unchanged, resulting
carnitine ratio). However, a preferential elimination of in an increased free to total carnitine ratio compared with
free carnitine could not be demonstrated, as investiga- controls [41].
tions of dialysate carnitine did not show a higher free to Data on carnitine muscle stores in HD patients are
total carnitine ratio compared with predialysis serum conflicting [36]. Bo¨hmer et al found a significant decrease
values [38]. in muscle carnitine during HD [35]. In a small study
In a recently published kinetic analysis, the reduction (N 5 4), Mingardi et al found predialysis free and total
of plasma free carnitine and plasma short-chain acyl car- muscle carnitine unchanged compared with healthy con-
nitine was attributed to a loss into dialysate not con- trols and suggested that the carnitine lost during dialysis
taining L-carnitine accompanied by loss of tissue carni- mainly originates from extracellular fluid [38].
tine significantly higher in bicarbonate compared with Additionally, data on the correlation of plasma and
acetate dialysis. However, even with a dialysate carnitine muscle carnitine in dialysis patients are conflicting [36].
concentration higher than predialysis plasma concentra- In contrast to the findings of Reichmann et al [45], in
tion during acetate dialysis (in contrast to bicarbonate controls, Savica et al [46] reported muscle free carnitine
dialysis), a decrease of free carnitine and an increase in to be significantly correlated to plasma free carnitine.
acetyl carnitine occurred, whereas nonacetyl short-chain In their study, muscle free and acetyl carnitine were
acyl carnitine decreased independently of dialysate ace- decreased compared with healthy controls, and the
tate content. This was due to a net tissue uptake of carni- depletion was more severe in long-term dialysis patients
tine and an associated tissue output of acetyl carnitine [46]. Atrophy of type I and type IIa muscle fibers is
significantly higher in acetate dialysis compared with bi- probably related to carnitine deficiency [47].
carbonate dialysis. RBC carnitine levels were not altered In adipose tissue of hyperlipidemic dialysis patients,
during dialysis sessions [39]. long-chain acyl carnitine is elevated with total carnitine
Furthermore, the changes of predialysis carnitine lev- comparable to healthy controls [48].
els observed in HD patients cannot simply be attributed Possible reasons for changed carnitine levels in HD
to carnitine losses during HD therapy, as weekly carni- patients are the loss of preferential elimination of short-
tine loss by dialysis therapy does not exceed urinary excre- chain acyl carnitine by the kidney, decreased intestinal
tion in healthy subjects. The weekly loss of free carnitine carnitine uptake, or decreased carnitine synthesis. Inves-
in hemofiltration patients (795 6 84 mmol) is even sig- tigations of precursors of endogenous carnitine synthesis
nificantly lower compared with urinary excretion in did not reveal lower levels in HD patients compared
with controls. In contrary, predialysis trimethyllysine washealthy controls (1534 6 135 mmol) [40].
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found to be fourfold increased compared with controls, tween hemolysis maximal point and hemolysis end point
and serum total and free carnitine levels [55]. They alsoalthough it is readily removed by dialysis [49].
Intestinal absorption seems to be unaffected in dialysis reported a significant negative correlation of erythropoi-
etin requirements and serum total and free carnitinepatients, although data are limited because of the small
sample size and the unphysiologically high oral carnitine levels, respectively.
Additionally, Albertazzi et al observed an increase ofload [40].
Another mechanism involved might be the disturbed erythrocyte Na1/K1 ATPase by L-carnitine supplemen-
tation [11]. Donatelli et al found a decrease in the abnor-transport of carnitine between various compartments
and/or the decreased activity of enzymes involved in mally high ATP content of erythrocytes in HD patients
treated with carnitine and attributed this effect to thecarnitine metabolism.
Carnitine palmitoyl transferase activity is impaired in prevention of accumulation of long-chain acyl carni-
tine, which inhibits the activity of erythrocyte Na1/K1CRF: In rats, the administration of intact parathyroid
hormone led to an significant decrease of CPT activity in ATPase [56].
Recently, a significant negative correlation of erythro-heart mitochondria without significant changes in heart
muscle carnitine content leading to reduced long- and cyte fluidity and rHuEPO requirement could be demon-
strated [57]. Treatment with low-dose L-carnitine (3 mg/short-chain fatty acid oxidation. Similar results were
found in CRF rats. Parathyroid hormone levels of CRF kg intravenously after each dialysis session) for four
months improved erythrocyte membrane fragility, asrats are not available in this study, but parathyroidecto-
mized CRF rats showed normal CPT activity [50]. tested by the acidified glycerol lysis test in a majority of
HD patients [58].Erythrocyte CPT activity is reduced in HD patients
[51]. In a case report, Uemura et al found reduced muscle In a double-blinded, randomized study, Labonia re-
ported a significant decrease in the rHuEPO requirementCPT activity in CRF patients, possibly related to hyper-
parathyroidism [52]. in a subgroup of carnitine-treated HD patients and thus
demonstrated the clinical significance of the data citedAs CPT has a transport function not only for long-
chain fatty acids but also for carnitine, the carnitine trans- earlier here [15].
port between various compartments might be compro-
mised, contributing to the changes in carnitine pattern STUDY DESIGN
observed in CRF. On the other hand, CPT activity in
We conducted a placebo-controlled, randomized, dou-erythrocytes of HD patients is restored by L-carnitine
ble-blinded study in 40 patients on maintenance HD ther-supplementation [53]. Therefore, it is not clear up until
apy. Twenty HD patients received L-carnitine (L-Carnitinnow whether the disturbances in carnitine metabolism de-
“Leopold”t; Leopold Pharma, Graz, Austria) intrave-scribed earlier here are linked primarily to a state of sec-
nously after each dialysis session (carnitine), and 20 pa-ondary CPT abnormality in uremia or to the reduced avail-
tients received placebo (0.9% saline). L-carnitine wasability of free carnitine in relation to increased demand.
administered over a period of eight months. Two carni-
tine dosages were used: 15 patients received 5 mg/kg and
CARNITINE AND ANEMIA IN 5 patients received 25 mg/kg. In placebo-treated patients
HEMODIALYSIS PATIENTS (controls), corresponding volumes of saline were admin-
istered to 15 and 5 patients, respectively.Trovato et al reported an increase in hematocrit in
HD patients treated with oral L-carnitine for one year Only patients on maintenance HD for more than six
months with a stable rHuEPO requirement were eligible:[10]. Vacha et al found the same effect in patients treated
with 1 g intravenous L-carnitine for 120 days [12]. The In a run-in phase of six months, a stable hemoglobin
level of 9 to 12 g/dl had to be obtained with a stableassumption of the authors—that L-carnitine might act
via stabilization of erythrocyte membranes by facilitating rHuEPO dose. Patients with documented blood loss for
any reason (for example, gastrointestinal bleeding, sur-the uptake of structural lipids—was supported by the
findings of Farrell et al, who reported an increased accu- gery, infection, or malignancy) were excluded. No trans-
fusions were allowed during six months before study entry.mulation of 14C in liver phospholipids and triacylglycerols
after injection of 14C-labeled acetyl carnitine compared Intravenous iron (iron saccharate, Ferrivenint; Laevo-
san, Linz, Austria) was substituted after each dialysiswith 14C-labeled acetate [54]. Thus, the entry of acetate in
major biosynthetic pathways is enhanced by L-carnitine, session in a dose of 20 mg per dialysis during the run-
in phase and the first four months of the study irrespec-and furthermore, especially lipids, which are major com-
pounds of the erythrocyte membrane, are affected. tive of ferritin levels or transferrin saturation. Iron ther-
apy was withdrawn thereafter.Matsumura et al investigated the relationship of carni-
tine levels and erythrocyte osmotic fragility in 26 HD In all patients, the RBC count was performed monthly,
and the rHuEPO dose was adjusted monthly accordingpatients and found a significant negative correlation be-
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to RBC results. rHuEPO dose was changed in steps of follow-up because of a change in dialysis unit for private
approximately 25% when an alteration of hemoglobin reasons. Two more patients were excluded for evaluation
of more than 1 g/dl compared with study entry was ob- at T8 because of surgical procedures during the second
served. A response to carnitine treatment was defined phase of the study.
as a decrease in rHuEPO requirement after four months Thus, at T4, 37 patient were evaluable (19 carnitine,
of carnitine substitution. 18 placebo). Twenty-eight patients finished the study (12
Serum ferritin, transferrin, and transferrin saturation carnitine, 16 placebo) and were evaluable at T8.
were measured every two months in order to monitor
iron status. The rHuEPO resistance index (ERI; weekly Laboratory investigations
rHuEPO dose per gram of hemoglobin achieved with Blood samples for L-carnitine determination in plasma
that dose) was calculated to provide a more individual- and erythrocytes were obtained from the arteriovenous
ized measure of rHuEPO requirement. fistula before the dialysis procedure and were centri-
In a randomly selected subgroup of HD patients, fuged within one hour of sampling. L-carnitine was deter-
erythrocyte survival time was determined by Cr-51 label- mined radioenzymatically according to the method of Ce-
ing. In another subgroup, iron content of liver in relation
derblad and Lindestedt [59] with several modifications as
to muscle iron was determined by magnetic resonance
described earlier here [60]. After deproteinization withimaging. These investigations were performed at study
perchloric acid (0.1 mol/liter), free carnitine reacts with 14-entry (T0), after four months of iron and carnitine substi-
C-acetylcoenzyme A to 14-C-acetyl-L-carnitine, catalyzedtution (T4), and after four further months of carnitine
by carnitine-acetyl-transferase. N-methyl-maleimide wassubstitution without iron therapy (T8), respectively.
added for trapping free coenzyme A. The excess of 14-Standard bicarbonate dialysis was performed three
C-acetylcoenzyme A was bound by ion exchange resinetimes per week, with either high-flux or low-flux dialyz-
(Dowex 1 3 8, chloride form 400 mesh). Residual radio-ers. Target Kt/V for urea was more than 1.3. The distribu-
activity was proportional to the amount of 14-C-acetyl-tion of dialyzers used was comparable between both
L-carnitine and was measured in a liquid scintillationgroups, as was the application of hemodiafiltration. Dial-
counter. The concentration was calculated from a cali-ysate acetate content was 3.0 mmol/liter in all patients.
bration curve (5 to 50 mmol/liter) considering sampleThe study protocol was approved by the local ethical
dilution by pretreatment. Total L-carnitine is determinedcommittee. Written informed consent was obtained from
after saponification. The portion of short-chain acyl car-each patient before T0. Informed consent additionally
nitine (C3 to C10) is calculated by the difference betweenwas obtained for determination of erythrocyte survival
time and liver iron content by magnetic resonance im- L-carnitine content before and after saponification. Data
aging, respectively. for RBC carnitine were given as nmol per gram of hemo-
globin in the cell fraction.
METHODS Erythrocyte survival time
Patient characteristics
The RBC survival test determined the functional half-
Forty patients on maintenance HD were investigated. clearance time of Cr-51–labeled isologous red cells.
Patients received L-carnitine or placebo (controls) as Whole blood was drawn on day 1 into an acid-citrate-
described earlier here. Patients and controls were com- dextrose containing syringe. One hundred mCi (3.7 MBq)
parable with regard to age (54.3 6 17.0 vs. 51.3 6 15.2 of Cr-51 was added and incubated for 20 minutes. The
years, NS), sex (8 females and 12 males vs. 11 females reaction was stopped by adding ascorbic acid and incu-
and 9 males, NS), duration of dialysis therapy (30.0 6
bating the mixture for another 10 minutes.
17.5 vs. 43.2 6 49.8 months, NS), and underlying renal
The tracer was injected intravenously. Anticoagulateddisease.
whole plasma samples were drawn at 15 and 30 minutesVitamin B12 (279.7 6 137.5 vs. 288.8 6 71.3 pmol/liter,
after injection from the contralateral arm and consecu-NS), folic acid (36.1 6 17.1 vs. 33.6 6 17.9 nmol/liter, NS),
tively three times a week for three weeks immediatelyintact parathyroid hormone (266.2 6 204.5 vs. 218.6 6
before dialysis. Based on the whole blood and plasma204.4 pg/ml, NS), and aluminum plasma levels (33.7 6
counts and the individual sample hematocrit, the net23.7 vs. 27.1 6 14.6 mg/liter, NS) were comparable be-
tagged RBC counts were expressed as the percentage oftween both groups.
arithmetic mean of the two-day 1-values and plotted.Five patients received renal transplants during the
Half-time was calculated from the linear regression fit ofstudy. Three patients died (myocardial infarction, sepsis,
these data points using Microcal Origin software (V 3.54;and postoperative complications after mitral valve sur-
Nicrocal Inc., Nothhamptom, MA, USA). The range ofgery) without suspected relationship to the study. One
patient withdrew consent, and one patient was lost for normal values was set at 28 to 34 days [61].
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Fig. 1. The effect of L-carnitine and iron sup-
plementation compared with placebo and iron
on hemoglobin levels (g/dl) of patients on main-
tenance hemodialysis at study entry (T0) and
after four (T4) and eight (T8) months. Carnitine-
treated patients are further subdivided in re-
sponders (N 5 8) and nonresponders (N 5 11).
Abbreviations are: T0, study entry; T4, four
months of supplementation with L-carnitine or
placebo and iv iron; T8, four further months
of supplementation with L-carnitine or placebo
without iv iron. Symbols are: ( ) placebo; (h)
carnitine; ( ) responders; (j) non-responders.
Table 1. Plasma carnitine levels (mmol/liter) at study entry (T0),Magnetic resonance imaging
after 4 months of treatment with L-carnitine (CA) and iron or
placebo (CO) and iron (T4), and after fourMagnetic resonance images were obtained with a 1.0-T
further months of treatmentimager (Gyroscan T 10-NT; Phillips, Eindhoven, The Neth-
erlands). Unenhanced imaging protocols included T2- CO CA CA5 CA25
T (N 5 20) (N 5 20) (N 5 15) (N 5 5)weighted fast-spin echo sequences (ultrashort turbo spin
P-FC 0 31.8 6 12.6 30.8 6 11.8 29.8 6 11.7 33.6 6 13.1echo sequence) in the axial and coronal plane (repetition
4 31.4 6 11.4 42.6 6 24.4 32.9 6 12.6 87.7 6 5.6ctime msec/echo time msec 5 3000/120), T1-weighted
8 32.7 6 12.8 42.3 6 24.4a 32.1 6 12.4 72.7 6 28.1c
spin-echo images (425/15) in the axial plane, and a mixed P-TC 0 57.0 6 20.1 52.8 6 17.6 51.5 6 18.5 56.6 6 15.8
4 55.0 6 15.7 72.2 6 32.9a 59.4 6 18.0 132.0 6 6.2csequence (1800/20; TRIR/TI 1400/400). All sequences
8 59.9 6 18.3 80.8 6 29.1a 61.7 6 17.2 138.0 6 25.5cwere obtained by using the body coil. Other parameters
P-AC 0 25.4 6 12.5 22.0 6 10.0 21.6 6 11.4 23.0 6 3.5
included field of view: 375/1.4; slice thickness: 10 mm, 4 23.8 6 6.2 29.7 6 9.9a 26.6 6 7.9 44.3 6 0.6c
8 27.2 6 7.4 38.5 6 17.6b 29.6 6 6.8 65.3 6 8.6c0.1 mm intersection gap; matrix size 256 3 192; and
P-F/TC 0 0.56 6 0.12 0.59 6 0.14 0.59 6 0.16 0.58 6 0.08signals averaged, respectively, 1 in mixed sequences. 4 0.56 6 0.08 0.57 6 0.10 0.55 6 0.10 0.66 6 0.01c
8 0.54 6 0.08 0.51 6 0.08 0.51 6 0.07 0.51 6 0.12
Statistics
L-carnitine was administered in a dose of either 5 mg (CA5) or 25 mg (CA25)
L-carnitine/kg body weight per hemodialysis session. Abbreviations are: P-FC,Descriptive results are shown as the mean value 6
plasma free carnitine; P-TC, plasma total carnitine; P-AC, plasma acyl carnitine;
standard deviation; one- or two-tailed student’s t-test for P-F/TC, plasma free-to-total carnitine ratio.
a P , 0.05 vs. T0paired or unpaired samples, Fisher’s exact test, and Spear-
b P , 0.05 vs. controls
man’s signed rank correlation were used as appropriate. c P , 0.05 vs. carnitine 5 mg
Results at T4 are discriminated for patients treated
with 5 and 25 mg L-carnitine and for responders and
nonresponders, respectively. At T8, the results are only
higher hemoglobin levels at T4 compared with T0 (11.6 6shown for carnitine and placebo-treated patients, respec-
0.6 and 11.2 6 0.6 g/dl, NS) with a reduced rHuEPOtively, to avoid small sample numbers.
dose (discussed later here).
RESULTS Carnitine levels at baseline
Red blood cells counts during the study Plasma and erythrocyte total, free, and short-chain
acyl carnitine levels were comparable in the two groupsThere was no difference in RBC counts between
at study entry (Tables 1 and 2).groups during the study, and hemoglobin was maintained
Plasma free carnitine was below the reference rangestable during the study according to protocol (Fig. 1).
(34 to 52 mmol/liter) in a majority of patients (26 out ofPatients responding to L-carnitine treatment had higher
40 patients, 10 out of 21 males, 16 out of 19 females).hemoglobin levels at T0 compared with nonresponders.
Plasma short-chain acyl-carnitine levels were above theThis difference below statistical significance was main-
tained throughout the study, and responders achieved reference range (1 to 7 mmol/liter for females, 10 to 18
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Table 2. Erythrocyte carnitine levels (nmol/g Hb) at study entry (T0), after 4 months of treatment with L-carnitine and iron or placebo
and iron (T4), and after four further months of treatment with L-carnitine or placebo without iron (T8)
CO CA CA5 CA25
T (N 5 20) (N 5 20) (N 5 15) (N 5 5)
E-FC 0 109.8 6 51.0 91.3 6 25.9 88.6 6 24.7 99.2 6 30.8
4 101.1 6 51.3 153.3 6 73.4ac 138.9 6 60.9c 220.7 6 103.7b
8 134.6 6 52.6 215.8 6 164.1 140.1 6 26.5 443.0 6 205.0b
E-TC 0 247.8 6 83.9 226.9 6 662 222.3 6 66.3 240.8 6 71.3
4 254.3 6 100.3 353.4 6 140.8ac 328.6 6 114.4c 469.0 6 221.7b
8 249.3 6 80.2 358.6 6 247.3 246.9 6 63.5 693.7 6 309.5b
E-AC 0 145.4 6 57.8 134.9 6 46.0 132.5 6 48.1 142.3 6 43.1
4 153.1 6 55.4 200.8 6 76.2ac 191.0 6 66.1c 246.8 6 119.3
8 115.5 6 43.0 142.5 6 88.6 106.3 6 46.2 251.0 6 105.4b
E-F/TC 0 0.44 6 0.11 0.41 6 0.07 0.41 6 0.08 0.41 6 0.04
4 0.39 6 0.08 0.43 6 0.10 0.42 6 0.11 0.74 6 0.01b
8 0.54 6 0.08 0.60 6 0.09c 0.58 6 0.10 0.64 6 0.02
L-carnitine was administered in a dose of either 5 mg (CA5) or 25 mg (CA25) L-carnitine/kg body weight per hemodialysis session. Abbreviations are: CA,
l-carnitine treated patients; CA5, L-carnitine 5 mg/kg/HD; CA25, L-carnitine 25 mg/kg/HD; CO, placebo treated patients; E-FC, erythrocyte free carnitine; E-TC,
erythrocyte total carnitine; E-AC, erythrocyte acyl carnitine; E-F/TC, erythrocyte free-to-total carnitine ratio.
a P , 0.05 vs. controls
b P , 0.05 vs. carnitine 5 mg
c P , 0.05 vs. T0
Table 3. Carnitine levels at study entry: Males compared to females stronger (r 5 0.51, P , 0.001), whereas the plasma free
to total carnitine ratio did not correlate with erythrocyteMales Females
(N 5 21) (N 5 19) P carnitine levels (Table 4).
P-FC lmol /liter 31.3 6 12.0 35.4 6 12.5a 26.7 6 10.0 ,0.05
P-TC lmol /liter 54.9 6 18.8 59.7 6 20.6 49.5 6 15.4 0.09, NS Carnitine levels during supplementation
P-AC lmol /liter 23.7 6 11.3 24.4 6 14.2 22.8 6 7.1 NS
All plasma carnitine fractions increased in carnitineP-F/TC 0.57 6 0.12 0.61 6 0.15 0.53 6 0.08 0.06, NS
E-FC nmol /g Hb 107.1 6 15.8 104.6 6 45.9 109.9 6 46.9 NS treated patients after four months of carnitine supple-
E-TC nmol /g Hb 247.3 6 82.0 239.5 6 88.5 255.8 6 75.7 NS mentation with total and acyl carnitine levels reaching
E-AC nmol /g Hb 140.2 6 51.8 135.0 6 58.7 145.9 6 43.9 NS
a significant difference at T4 compared with T0. PlasmaE-F/TC 0.43 6 0.09 0.44 6 0.12 0.43 6 0.07 NS
free carnitine reached an almost significant differenceAbbreviations are: P-FC, plasma free carnitine; P-TC, plasma total carnitine;
P-AC, plasma acyl carnitine; P-F/TC, plasma free-to-total carnitine ratio; E-FC, (P 5 0.055). After eight months of carnitine supplemen-
erythrocyte free carnitine; E-TC, erythrocyte total carnitine; E-AC, erythrocyte tation, the difference between T0 and T8 was significantacyl carnitine; E-F/TC, erythrocyte free-to-total carnitine ratio; NS, not signifi-
cant. in all fractions. Plasma free carnitine and plasma total
a P , 0.05 vs. females carnitine increased within only the first four months and
showed no further increase thereafter. The ongoing in-
crease in acyl carnitine was not significant. P-F/T carni-
tine ratio did not change significantly in carnitine-treatedmmol/liter for males) in a majority of patients (19 out of
patients (Table 1).19 females, 14 out of 21 males). Plasma free carnitine
In erythrocytes, all carnitine fractions increased afterwas significantly higher in males compared with females,
four months of carnitine supplementation, reaching sig-whereas plasma total carnitine was not significantly dif-
nificance compared with controls as well as to levels seenferent. Plasma short-chain acyl carnitine showed no sex-
at study entry. The free to total carnitine ratio showedrelated difference. Plasma free to total carnitine ratio
no change after four months of supplementation. Eryth-was lower in females near statistical significance. RBC
rocyte free carnitine showed a further increase after eightcarnitine levels at study entry were only slightly higher
months of supplementation, whereas acyl carnitine de-in females, and the RBC free to total carnitine ratio
creased to levels comparable to study entry. These changesshowed no sex-related difference (Table 3).
were near significance (P 5 0.09 and 0.06, respectively).Plasma free carnitine and plasma short-chain acyl car-
The free to total carnitine ratio therefore increased sig-nitine levels showed no significant correlation. Erythro-
nificantly compared with T0 and T4 (Table 2).cyte free carnitine and erythrocyte short-chain acyl carni-
Patients receiving 25 mg carnitine per kg body weighttine showed a weak positive correlation. The free to total
achieved significantly higher carnitine levels comparedcarnitine ratio in both compartments was not related to
with patients receiving 5 mg/kg in all plasma and erythro-total carnitine levels. There was only a moderate positive
cyte carnitine fractions after four and eight months ofcorrelation between plasma free carnitine and erythro-
supplementation (Tables 1 and 2).cyte carnitine levels. The positive correlation of plasma
total carnitine and erythrocyte free carnitine was slightly After four months of L-carnitine supplementation in a
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Table 4. Carnitine levels at study entry: Correlation of carnitine fractionis in plasma and erythrocytes
P \ r P-FC P-TC P-AC P-F/TC E-FC E-TC E-AC E-F/TC
P-FC — 0.82 0.29 0.47 0.41 0.46 0.34 0.12
P-TC c — 0.79 20.01 0.51 0.49 0.32 0.23
P-AC NS (0.07) c — 20.66 0.41 0.33 0.17 0.25
P-F/TC b NS c — 20.08 20.01 0.04 20.11
E-FC b c c NS — 0.81 0.40 0.54
E-TC b b a NS c — 0.86 0.02
E-AC a a NS NS a c — 0.49
E-F/TC NS a NS NS c NS b —
Abbreviations are: P-FC, plasma free carnitine; P-TC, plasma total carnitine; P-AC, plasma acyl carnitine; P-F/TC, plasma free-to-total carnitine ratio; E-FC,
erythrocyte free carnitine; E-TC, erythrocyte total carnitine; E-AC, erythrocyte acyl carnitine; E-F/TC, erythrocyte free-to-total carnitine ratio; NS, not significant.
P, P value; r, correlation coefficient.
a, P , 0.05; b, P , 0.01; c, P , 0.001
Table 5. Plasma and red blood cell (RBC) carnitine of all responders
(CAR, N 5 8) compared to non-responders (CANR, N 5 11)
at study entry (T0) and after four months of treatment
with L-carnitine and iron (T4)
CAR CANR CAR CANR
T Plasma lmol /liter RBC nmol /g Hb
FC 0 35.4 6 14.8 27.0 6 8.8 110.2 6 28.7a 77.9 6 14.7
4 49.4 6 29.2 37.8 6 20.6 156.5 6 58.9 151.2 6 85.1
TC 0 63.0 6 18.1a 45.1 6 14.6 263.4 6 78.3 204.5 6 46.9
4 82.0 6 39.5 65.4 6 27.5 343.4 6 125.9 360.3 6 156.6
AC 0 27.5 6 7.8a 18.1 6 10.2 151.9 6 52.6 126.2 6 40.1
4 32.6 6 11.8 27.7 6 8.5 186.8 6 76.7 210.7 6 78.4
F/TC 0 0.55 6 0.12 0.61 6 0.16 0.43 6 0.07 0.39 6 0.07
4 0.58 6 0.10 0.56 6 0.10 0.46 6 0.10 0.40 6 0.09
Abbreviations are: FC, free carnitine; TC, total carnitine; AC, acyl carnitine;
F/TC, free-to-total carnitine ratio.
a P , 0.05 vs. non-responders Fig. 2. The plasma-erythrocyte ratio of total carnitine concentration
in responders (N 5 5) and nonresponders (N 5 9) treated with low-
dose L-carnitine (5 mg/kg body weight per hemodialysis session). Sym-
bols are: (h) T0, study entry; (j) T4, after 4 months of treatment with
low-dose carnitine and iron; * P , 0.05 compared to T0.
dose of 5 mg/kg/HD, plasma free carnitine levels showed
only a slight increase, and 10 of 14 patients still had free
carnitine below the reference range. The increase of
Recombinant human erythropoietin requirementplasma total and acyl carnitine in those patients was more
pronounced, although the difference was significant only At T0, rHuEPO requirement (U/kg/week) was compa-
after eight months of supplementation (Table 1). rable between carnitine-patients and controls (172.0 6
In erythrocytes, all carnitine fractions increased sig- 118.0 and 143.9 6 82.4 U/kg/week, respectively, NS).
nificantly after four months of low-dose carnitine supple- After T4, the rHuEPO requirement decreased in car-
mentation, the RBC free to total carnitine ratio did not nitine patients and was unchanged in controls (152.3 6
change. Acyl and total carnitine decreased during the sec- 118.8 vs. 158.6 6 105,4 U/kg/week, NS). The decrease
ond four months of low-dose carnitine supplementation, in rHuEPO dose in carnitine patients evaluable at T4
whereas RBC free carnitine remained stable (Table 2). (N 5 19) was near statistical significance (172.0 6 118.0
Patients responding to carnitine supplementation had vs. 152.3 6 118.8 U/kg/week, P 5 0.07, NS), whereas the
higher plasma and RBC levels of all carnitine fractions changes in rHuEPO dose in absolute numbers differed
at T0 compared with nonresponders (Table 5). During significantly between groups (219.7 6 44.7 vs. 6 15.0 6
supplementation of carnitine in responders treated with 43.8 U/kg/week, P , 0.05). ERI decreased significantly
L-carnitine 5 mg/kg/HD, plasma free and total carnitine in carnitine patients [16.0 6 11.0 vs. 13.6 6 10.5 (U/kg/
levels remained unchanged after four months of L-carni- week)/gHb, P , 0.02; Fig. 3].
tine supplementation, whereas erythrocyte carnitine levels Eight of 19 (42%) patients evaluable in the carnitine
increased, leading to a decrease of plasma/erythrocyte group responded to carnitine supplementation, reducing
carnitine ratio (Fig. 2; Table 6). In nonresponders, how- their rHuEPO dose by 57.1 6 44.5 U/kg/week (236.9 6
ever, both plasma and erythrocyte carnitine levels in- 23.3%), reaching a significant difference compared with
T0 (183.7 6 131.7 vs. 126.6 6 127.9 U/kg/week, P ,creased.
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Table 6. Plasma and RBC carnitine levels in low-dose carnitine responders (CAR, N 5 5) compared to non-responders (CANR, N 5 9)
at study entry (T0) and after four months of treatment with L-carnitine 5 mg/kg/HD and iron (T4)
Plasma lmol /liter RBC nmol /g Hb
T CAR CANR P CAR CANR P
FC 0 34.6 6 16.4 26.6 6 8.7 NS 110.3 6 26.7 76.8 6 16.1 ,0.05
4 33.8 6 14.0 32.4 6 12.5 NS 154.3 6 70.7 130.4 6 57.3a NS
TC 0 64.4 6 19.3 43.9 6 15.6 0.051, NS 267.0 6 81.4 202.0 6 49.6 0.08, NS
4 61.6 6 22.4 58.2 6 16.5b NS 343.8 6 152.4 320.1 6 97.1b NS
AC 0 29.6 6 9.0 17.3 6 11.3 NS 154.0 6 58.6 124.7 6 42.3 NS
4 27.8 6 10.4 25.9 6 6.6 NS 190.1 6 93.3 191.5 6 52.5b NS
F/TC 0 0.52 6 0.15 0.62 6 0.17 NS 0.43 6 0.08 0.39 6 0.08 NS
4 0.55 6 0.11 0.55 6 0.10 NS 0.46 6 0.13 0.40 6 0.09 NS
Abbreviations are: FC, free carnitine; TC, total carnitine; AC, acyl carnitine; F/TC, free-to-total carnitine ratio; NS, not significant.
a P , 0.05 vs. T0
b P , 0.01 vs. T0
0.001). The response rate was higher in patients receiving
25 mg/kg L-carnitine (responders: 3/5 patients) com-
pared with patients receiving 5 mg/kg L-carnitine (re-
sponders: 5/14 patients) without reaching statistical sig-
nificance (P . 0.05). However, mean rHuEPO dose and
ERI in patients treated with 5 mg/kg L-carnitine did not
change at T4 compared with T0. In patients treated with
25 mg/kg L-carnitine, the decrease in rHuEPO dose was
also not significant because of the small sample number,
as was the decrease in the ERI [12.3 6 3.5 vs. 7.3 6 3.6
(U/kg/week)/gHb, P 5 0.1, NS].
After withdrawal of iron supplementation and admin-
istration of L-carnitine for another four months (T8),
the rHuEPO requirement increased in both L-carnitine
and placebo-treated patients [rHuEPO dose at T8:
180.7 6 102.7 and 172.6 6 116.2 U/kg/week, respectively,
NS; ERI: 17.2 6 10.0 (U/kg/week)/gHb and 16.4 6 11.1
(U/kg/week)/gHb, respectively, NS] without significant
differences within groups between T4 and T8.
At T8, only two responders were evaluable, and in
both patients, rHuEPO requirement was lower at T8
compared with T0, indicating an ongoing beneficial effect
of L-carnitine. Two further patients who showed no
change in rHuEPO dose at T4 compared with T0 reduced
rHuEPO requirement in spite of withdrawal of iron sup-
plementation, suggesting a delayed beneficial effect of
L-carnitine.
In all patients treated with L-carnitine 25 mg/HD and
evaluable at T8, an increase in the rHuEPO requirement
compared with T4 was observed, suggesting a lack of
beneficial effect of increased L-carnitine dosage.Fig. 3. The rHuEPO requirement and rHuEPO resistance index
(ERI) in L-carnitine- and iron-treated hemodialysis patients (CA). L- Because of the small number of patients evaluable at
carnitine–treated patients are further subdivided into patients receiving T8 in either subgroup, these results have to be interpretedeither 5 mg (CA5) or 25 mg (CA25) L-carnitine per kg body weight
with care.per hemodialysis session and in responders (CAR) and nonresponders
(CANR), respectively. Placebo- combined with iron-treated patients
served as controls (CO). Abbreviations are: ERI, rHuEPO resistance Carnitine levels and recombinant
index; CA, L-carnitine treated patients; CA5, L-carnitine, 5 mg/kg/ human erythropoietin requirementHD; CA25, L-carnitine, 25 mg/kg/HD; CAR, responders; CAN, non-
responders; CO, placebo-treated patients; T0, study entry; T4, after There was no significant correlation between the indi-
four months of treatment with L-carnitine and iron. Symbols are: (T0)
vidual rHuEPO requirement and carnitine levels at T0.study entry; (T4) after four months treatment with L-carnitine and
iron; * P , 0.05 compared to T0. Plasma free carnitine and plasma free to total carnitine
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Table 9. Correlation of carnitine levels with rHuEPO dose andTable 7. Correlation of carnitine levels with rHuEPO dose and
rHuEPO resistance index at study entry (T0, N 5 40) rHuEPO resistance index after four months of treatment
with L-carnitine or placebo and iron
EPO ERI
CA (N 5 19) CO (N 5 18)
r P r P
EPO, r P ERI, r P EPO, r P ERI, r P
P-FC 20.16 NS 20.18 NS
P-TC 20.04 NS 20.05 NS P-FC 20.62 ,0.01 20.63 ,0.01 20.25 NS 20.21 NS
P-TC 20.56 ,0.05 20.57 ,0.05 20.29 NS 20.28 NSP-AC 0.10 NS 0.11 NS
P-F/TC 20.23 0.15, NS 20.26 0.10, NS P-AC 20.33 NS 20.34 NS 20.24 NS 20.29 NS
P-F/TC 20.71 ,0.01 20.70 ,0.01 20.05 NS 0.03 NSE-FC 0.08 NS 0.06 NS
E-TC 0.20 0.22, NS 0.17 0.29, NS E-FC 20.23 NS 20.22 NS 0.42 NS 0.48 0.06, NS
E-TC 20.01 NS 0.01 NS 0.46 NS 0.51 ,0.05E-AC 0.23 0.15, NS 0.21 0.19, NS
E-F/TC 20.20 0.22, NS 20.20 0.22, NS E-AC 0.16 NS 0.18 NS 0.42 NS 0.45 0.08, NS
E-F/TC 20.43 NS 20.44 NS 0.14 NS 0.19 NSAbbreviations are: P-FC, plasma free carnitine; P-TC, plasma total carnitine;
P-AC, plasma acyl carnitine; P-F/TC, plasma free-to-total carnitine ratio; E-FC, Abbreviations are: CA, l-carnitine treated patients; CO, placebo treated pa-
erythrocyte free carnitine; E-TC, erythrocyte total carnitine; E-AC, erythrocyte tients; P-FC, plasma free carnitine; P-TC, plasma total carnitine; P-AC, plasma
acyl carnitine, E-F/TC, erythrocyte free-to-total carnitine ratio; EPO, rHuEPO acyl carnitine; P-F/TC, plasma free-to-total carnitine ratio; E-FC, erythrocyte free
dose (U/kg/week); ERI, rHuEPO resistance index (U/kg/week/g Hb); r, correla- carnitine; E-TC, erythrocyte total carnitine; E-AC, erythrocyte acyl carnitine; E-
tion coefficient; P, P value; NS, not significant. F/TC, erythrocyte free-to-total carnitine ratio; EPO, rHuEPO dose (U/kg/week);
ERI, rHuEPO resistance index (U/kg/week/g Hb); r, correlation coefficient; P,
P value; NS, not significant.
Table 8. Correlation of carnitine levels with rHuEPO dose and
rHuEPO resistance index after four months of treatment
with L-carnitine or placebo and iron (T4, N 5 37) Table 10. Correlation of carnitine levels at study entry (T0) and
changes in rHuEPO dose after four months of treatment withEPO ERI
L-carnitine (CA) and iron (T4) compared to T0 (N 5 19)
r P r P
CA
P-FC 20.49 ,0.01 20.48 ,0.01
r PP-TC 20.45 ,0.01 20.45 ,0.01
P-AC 20.29 NS 20.31 NS P-FC 20.22 NS
P-F/TC 20.44 ,0.01 20.41 ,0.05 P-TC 20.32 NS
E-FC 20.005 NS 0.03 NS P-AC 20.30 NS
E-TC 0.14 NS 0.17 NS P-F/TC 0.12 NS
E-AC 0.23 NS 0.26 NS E-FC 20.59 ,0.01
E-F/TC 20.21 NS 20.19 NS E-TC 20.45 0.051
E-AC 20.32 NSAbbreviations are: P-FC, plasma free carnitine; P-TC, plasma total carnitine;
P-AC, plasma acyl carnitine; P-F/TC, plasma free-to-total carnitine ratio; E-FC, E-F/TC 20.22 NS
erythrocyte free carnitine; E-TC, erythrocyte total carnitine; E-AC, erythrocyte
Abbreviations are: P-FC, plasma free carnitine; P-TC, plasma total carnitine;acyl carnitine, E-F/TC, erythrocyte free-to-total carnitine ratio; EPO, rHuEPO
P-AC, plasma acyl carnitine; P-F/TC, plasma free-to-total carnitine ratio; E-FC,dose (U/kg/week); ERI, rHuEPO resistance index (U/kg/week/g Hb); r, correla-
erythrocyte free carnitine; E-TC, erythrocyte total carnitine; E-AC, erythrocytetion coefficient; P, P value; NS, not significant.
acyl carnitine; E-F/TC, erythrocyte free-to-total carnitine ratio; EPO, rHuEPO
dose (U/kg/week); r, correlation coefficient; P, P value; NS, not significant.
showed a weak negative correlation with the individual
rHuEPO dose before carnitine supplementation without
This is in accordance with the negative correlation ofreaching significance.
erythrocyte carnitine levels at T0 and changes in rHuEPOErythrocyte total carnitine and acyl carnitine (E-AC)
requirement at T4 in carnitine patients: In patients treatedshowed a weak positive correlation with the rHuEPO
with L-carnitine, the decrease in the rHuEPO requirementdose. The erythrocyte free carnitine to total carnitine
was higher with higher RBC carnitine levels at baseline.ratio and the rHuEPO requirement therefore showed
an insignificant negative correlation (Table 7). Serum iron parameters
After four months of treatment with carnitine or pla-
At study entry, iron parameters were comparable be-cebo, there were significant negative correlations of
tween the two groups (serum ferritin: 632.1 6 466.0 inplasma free carnitine, plasma total carnitine, and P-F/
L-carnitine–treated patients and 605.5 6 398.4 mg/literTC to rHuEPO dose and ERI, which were attributable
in placebo-treated patients, NS; transferrin: 187.1 6 28.7to correlation in patients receiving carnitine (Tables 8
and 206.7 6 42.1 mg/dl, respectively, NS; transferrin satu-and 9). Placebo-treated patients, in contrast, showed a
ration 17.3 6 8.3% and 15.8 6 6.7%, respectively, NS).positive correlation of rHuEPO requirement and RBC
At T4, patients treated with L-carnitine showed acarnitine reaching significance for RBC total carnitine.
slight increase in serum ferritin levels (T0: 632.1 6 466.0Changes in rHuEPO dose at T4 were significantly cor-
mg/liter; T4: 664.8 6 428.5 mg/liter, NS), without differ-related to plasma free and total carnitine at T0: Patients
ence between responders and nonresponders or patientswith higher plasma free and total carnitine levels had a
more pronounced decrease in rHuEPO dose (Table 10). treated with 5 or 25 mg L-carnitine (data not shown).
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Transferrin and transferrin saturation did not change in DISCUSSION
any subgroup of carnitine patients. Disturbed carnitine metabolism in patients on mainte-
After the withdrawal of iron supplementation, serum nance HD has been reported by numerous investigators
ferritin levels decreased in both groups as expected [35–45]. However, the data on carnitine deficiency are
(L-carnitine–treated patients: 632.1 6 466.0 mg/liter at conflicting, as total plasma carnitine was found to be
T0 and 421.9 6 412.9 mg/liter at T8, NS; placebo-treated decreased [35–38], normal [42], or even increased [43,
44] compared with healthy controls [36]. Reports on thepatients: 605.5 6 398.4 mg/liter at T0 and 409.7 6 364.5
influence of age and sex on carnitine levels in hemodialy-mg/liter at T8, P , 0.05). Transferrin saturation de-
sis patients are rare.creased in both groups, with no significant difference
We found plasma-free carnitine below the referencebetween T0 and T4 in either group.
range and plasma acyl carnitine above the reference
range in a majority of our HD patients. The mean valuesMagnetic resonance imaging results
of plasma free and acyl carnitine therefore are lowerThere was no difference between groups concerning
and higher compared with the values for healthy controlsliver iron content as determined by magnetic resonance
reported in the literature, respectively. The plasma free/studies. During carnitine/placebo and iron coadministra-
total carnitine ratio was lower compared with data pub-
tion, there were no significant changes in liver iron con-
lished for healthy controls. These findings are in accor-
tent and no differences between groups. After with- dance with recently published studies [41, 62].
drawal of iron supplementation, liver iron content, as In addition, we observed a significant difference in
expected, showed a tendency to decrease without differ- plasma free carnitine levels of females compared with
ence between the groups (data not shown). males on maintenance HD as it was observed in healthy
controls [22], which is in contrast to findings of other
Erythrocyte survival investigators in HD patients [62].
Erythrocyte survival time was determined at study There was, however, no significant sex difference in
entry and was below the reference range (28 to 34 days) baseline erythrocyte carnitine levels of our patients. This
at T0 without a difference between the groups (L-carni- finding is in accordance with reports on erythrocyte car-
tine- and iron-treated patients, N 5 5: 21.8 6 2.3 days; nitine in healthy adults [22]. The erythrocyte total and
acyl carnitine levels in our study were higher. Free carni-placebo- and iron-treated patients, N 5 5: 22.4 6 4.2
tine levels were lower compared with the values for HDdays, NS). There was a significant negative correlation of
patients that Wanner et al reported [41].erythrocyte survival time ERI at T0 (r 5 20.73, P , 0.01).
Compared with published data for RBC carnitine frac-Furthermore, there was a significant negative correla-
tions in healthy controls, our patients show higher valuestion between plasma free and total carnitine and erythro-
for all RBC carnitine fractions. The RBC free to totalcyte survival time at T0 (plasma free carnitine: r 5 20.65,
carnitine ratio is only moderately decreased comparedP , 0.01; plasma total carnitine: r 5 20.66, P , 0.01).
with healthy controls [41, 63].Plasma acyl carnitine and F/T carnitine ratio as well as
As we did not demonstrate a correlation of free toerythrocyte carnitine levels did not correlate significantly
total carnitine ratio to total carnitine in both plasma andwith erythrocyte survival time.
RBCS, our results suggest mechanisms other than pureIn L-carnitine and iron-treated patients, there was a
carnitine depletion to be involved in disturbed carnitineslight increase of mean erythrocyte survival time (23.2 6
metabolism of HD patients.2.8 days) after four months of L-carnitine and treatment
Intravenous, oral, as well as dialysate L-carnitine sup-(T4), whereas in placebo- and iron-treated patients,
plementation was investigated by different authors, anderythrocyte survival time did not change (22.4 6 3.8
all routes of administration have been proven to be effi-
days). In only two responders out of five carnitine-
cient in increasing plasma carnitine levels. Giovenali et al
treated patients, erythrocyte survival was determined at administered L-carnitine over a period of 24 weeks in a
T4, who showed an increase of erythrocyte survival time dose of 2 g/day orally, 2 g/dialysis session, and 2 g per
of 15 and 20%, respectively. In nonresponders, erythro- 170 liter of dialysate (L-carnitine concentration 5 0.0725
cyte survival time did not change at T4. mmol/liter), increasing predialysis mean free plasma carni-
tine levels 3.2-fold, 2.7-fold, and 1.6-fold, respectively [47].
Side-effects In another study, three months of treatment with 1
No side-effects were observed. One diabetic patient mg/kg of L-carnitine per kg body weight three times
withdrew consent after two weeks of carnitine supple- a week intravenously after HD significantly increased
mentation, as he observed an increase in blood glucose plasma total and short- and long-chain acyl carnitine.
Free carnitine remained unchanged, and thus, the freeand insulin requirement.
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to total carnitine ratio decreased. In RBCs, low-dose randomized, placebo-controlled study in 24 patients and
could demonstrate a 38% reduction in rHuEPO dose incarnitine supplementation decreased total carnitine by
reduction of RBC free carnitine [41]. 13 patients treated with 1 g L-carnitine after each HD
session (17.9 6 2.8 mg/kg) for six months [15]. GlobalL-carnitine treatment with 5 mg/kg increased all plasma
and erythrocyte carnitine fractions to values above those osmotic fragility and endogenous erythropoietin levels
were not affected by L-carnitine, therefore, not account-reported for healthy controls without changing de-
creased the plasma free to total carnitine ratio and in- ing for this effect of carnitine on anemia. Seven patients
responded to carnitine-administration, whereas six pa-creased the RBC free to total carnitine ratio. Treatment
with 15 mg/kg increased plasma and RBC total, free, tients were nonresponders. At T0, responders had higher
rHuEPO requirements and higher endogenous erythro-and acyl carnitine more than three times above normal.
Six weeks of wash-out did not normalize these elevated poietin levels than nonresponders, although statistically
not significant. Thus, Labonia suggested rHuEPO resis-concentrations. Low RBC carnitine ester turnover was
suggested, and it was concluded that the L-carnitine tance as a consequence of carnitine deficiency, which
was corrected by L-carnitine supplementation in a sub-doses used in clinical trials might be much too high [41].
Our results showed no normalization of decreased group of patients [15].
In an uncontrolled study, Kavadias et al reported aplasma free carnitine after four or eight months of
L-carnitine supplementation in a dose of 5 mg/kg/HD. 50% reduction of rHuEPO requirement in all patients
studied by intravenous coadministration of 2 g L-carni-After four months, a majority of patients still had free
carnitine levels below the reference range (10 of 14 pa- tine postdialysis [17]. Boran et al found a significant
increase in hematocrit levels after three months of intra-tients). Initially, increased P-AC levels showed a further
increase under therapy. Therefore, the plasma F/TC ra- venous L-carnitine supplementation (0.04 to 0.06 g/kg/
week) and maintenance of the rHuEPO dose in 14 un-tio, which was initially decreased compared with healthy
controls, worsened further. Carnitine supplementation controlled HD patients [16]. With half of the former
rHuEPO dose and further carnitine supplementation,in a dose of 25 mg/kg/HD increased all plasma carnitine
fractions above the reference range in accordance to hematocrit decreased again, but was still significantly
higher compared with T0.Wanner et al [41].
These data demonstrate that the disturbance of carni- Our data suggest that carnitine supplementation re-
duces rHuEPO requirement in a subgroup of patientstine metabolism in HD patients is not simply a lack of
plasma free carnitine that can be restored with L-carni- on maintenance HD. The percentage of patients re-
sponding to four months of carnitine supplementationtine supplementation.
There are two studies published so far that have found was comparable to the results of Labonia [15]; the reduc-
tion in rHuEPO requirements, however, was lower, pos-a significant negative correlation of plasma total carni-
tine levels and rHuEPO requirement in HD patients [55, sibly related to different L-carnitine dosage [15].
In the clinical studies currently published, the interde-64]. Plasma free carnitine and rHuEPO dose showed no
correlation. In anemic patients (hematocrit of less than pendence of carnitine and iron supplementation were
not investigated. In the study of Labonia, patients re-30% or rHuEPO therapy), plasma free and total carni-
tine were significantly lower compared to nonanemic ceived oral or intravenous iron supplementation as re-
quired according to serum ferritin levels and transferrinpatients (hematocrit of more than 30% without rHuEPO
therapy) [64]. saturation throughout the study [15]. An influence of
iron parameters on carnitine response was not reported.In contrast to these findings, we could not confirm a
significant correlation of plasma or erythrocyte carnitine Our investigation of carnitine supplementation and iron
parameters could not reveal an interdependence of theseand rHuEPO requirement at T0 (Table 7). Plasma free
carnitine showed a negative correlation near significance, metabolic processes. Neither an influence on iron utiliza-
tion or on mobilization of body iron stores by L-carnitinewhereas plasma total carnitine did not show any correla-
tion to the rHuEPO requirement. supplementation could be demonstrated.
Responders and nonresponders did not differ in ironAfter four months of L-carnitine supplementation,
there was a significant negative correlation of plasma parameters, rHuEPO requirement, age, duration of dial-
ysis. At study entry, however, responders had higherfree and total carnitine to rHuEPO dose in our study,
whereas plasma carnitine levels did not correlate. plasma and RBC carnitine levels. Nonresponders achieved
those levels after four months of carnitine supplementa-In 1992, Be´rard et al [14] reported two cases of hemo-
dialyzed children with erythropoietin-hyporesponsive- tion. Therefore, our results may suggest that in HD pa-
tients, higher plasma free carnitine levels are necessaryness (240 to 360 U/kg/week) whose hematocrit could be
improved by administration of 1 to 3 mg/kg L-carnitine for the desired therapeutic results than in healthy sub-
jects because of the disturbed carnitine pattern of HDintravenously at the end of dialysis sessions.
Based on these observations, Labonia performed a patients. Thus, we perceived evidence that severely car-
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nitine-depleted patients might need a higher dosage or APPENDIX
longer supplementation of carnitine in order to reduce Abbreviations used in this article are: acylCoA, acyl coenzyme A;
ATP, adenosine triphosphate; CPT, carnitine palmitoyl transferase;the rHuEPO requirement.
CRF, chronic renal failure; ERI, rHuEPO resistance index; HD, hemo-A shift of carnitine from plasma into RBCs was ob-
dialysis; NS, not significant; RBCs, red blood cells; rHuEPO, recombi-
served only in responders supplemented with a low dose nant human erythropoietin; T0, study entry; T4, after four months of
iron and carnitine supplementation; T8, after four further months ofof L-carnitine. This effect was absent in nonresponders.
carnitine supplementation without iron therapy.A disturbed carnitine transport between various com-
partments in addition to carnitine deficiency might con-
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